Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells

作者：Gatto Barbara^*

来源：Current Opinion in Investigational Drugs, 2008, 9(11): 1216-1227.

Atacicept (TACI:Fc5) is a homodimeric fusion protein obtained through recombinant DNA technology being developed by Merck Serono SA, under license from ZymoGenetics Inc, for the potential treatment of B-cell diseases. Atacicept is undergoing phase II/III clinical trials for systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, as well as for several B-cell malignancies.

• 出版日期2008-11